PRINCETON, N.J., March 9 /PRNewswire/ -- The Bull Market Report (http://www.bullmarket.com/), an online investment newsletter focused on long- term growth and income-generating stocks, announced that it has published an in-depth report on companies involved in bird flu research, highlighting Hemispherx Biopharma (AMEX:HEB), Generex Biotechnology (NASDAQ:GNBT), Applera Corp-Applied Biosystems Group (NYSE:ABI), and Carrington Laboratories (NASDAQ:CARN), among others.
All paid and trial subscribers to The Bull Market Report can now receive immediate access to the newsletter's exclusive daily reports. As a subscriber, you'll also gain access to our latest investment moves. Start your 14-day free trial today: https://www.bullmarket.com/subscribe/index.php?refer=BMR98 In its report, The Bull Market Report wrote: "Should H5N1 mutate into a human strain, our success containing it and developing a vaccine will ride on our ability to identify it. Detection is going to be key. As with the other areas discussed, there are plenty of firms with a hand in producing kits that can recognize distinguishing gene sequences in hours rather than days." In its coverage, The Bull Market Report looked at the following topics:
-- What metrics should investors look at when examining smaller biotechs
involved in bird flu research?
-- What are some of the larger companies that could benefit from bird flu
research?
-- What is the best strategy to employ for long-term investors interested
in investing in this niche of the biotech sector?
-- What two non-healthcare-related companies look like possible
beneficiaries from the concern over bird flu? About The Bull Market Report:
Launched in 1997, The Bull Market Report has a strong track record of creating wealth for its subscribers by providing sound, long-term investing advice. The Bull Market Report's Recommended List includes over 50 companies across all major industries, including Financials, Healthcare, Energy, Technology, and Retail, among others. The Bull Market Report is one of the oldest continuously published investment newsletters online.
NOTE: This release was published by Indie Research Advisors, LLC (CRD #131926), a registered investment advisor with the NASD and State of NJ. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
CONTACT: Marcie Martin, +1-888-278-5515 DATASOURCE: Indie Research Advisors, LLC CONTACT: Marcie Martin, Indie Research Advisors, LLC, +1-888-278-5515 Web site: http://www.bullmarket.com/
|